A diagnostic biomarker for ALS would permit early intervention with disease-modifying
therapies while a biomarker for disease activity could accelerate the pace of drug discovery …

Objective. To evaluate serum and cerebrospinal fluid (CSF) levels of phosphorylated
neurofilament heavy (pNfH), and to compare these to levels of neurofilament light (NfL), as …

There is a need for biomarkers for amyotrophic lateral sclerosis (ALS), to support the
diagnosis of the disease, to predict disease progression and to track disease activity and …

Objective: To determine the diagnostic performance and prognostic value of phosphorylated
neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) in CSF as possible …

Objective To determine whether serum phosphorylated neurofilament heavy chain (pNfH)
levels are elevated before patients were diagnosed with sporadic or familial ALS, and what …

Objective To identify preferred neurofilament assays and clinically validate serum
neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) as prognostic and …

Background The phosphorylated neurofilament heavy subunit (pNF-H), a major structural
component of motor axons, is a promising putative biomarker in amyotrophic lateral …

Objective Phosphorylated neurofilament heavy chain (pNfH) levels are elevated in
cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS). Instead of …

Background To allow early diagnosis and monitoring of disease progression, there is a need
for biomarkers in amyotrophic lateral sclerosis (ALS). Neurofilaments (NF) are emerging …

OBJECTIVE: Neurofilaments are leading neurochemical biomarkers for amyotrophic lateral
sclerosis (ALS). Here, we investigated the effect of preanalytical factors on neurofilament …